Cash-laden Vertex Pharmaceuticals has followed up this month’s news of its $4.9 billion buy of US biotech company Alpine Immune Sciences with an announcement of 23 April 2024
Like its rivals in the GLP-1 space, Eli Lilly (NYSE: LLY) continues to explore the potential of Zepbound (tirzepatide) in addressing the broad range of comorbid 18 April 2024
A US judge has dismissed a legal claim from pharma major Eli Lilly alleging that an online pharmacy illegally sold an unauthorized compounded version of the com 15 April 2024
Increasing demand for targeted therapies is driving demand in the antibody discovery market, finds industry analyst Future Market Insights. 8 April 2024
Polish biotech company PolTREG has published new data on PD-1+ T-cells which it said prove their usefulness as a biomarker for the efficacy of its candidate PTG 4 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.